Alumis

Alumis Inc. (NASDAQ: ALMS) is a clinical-stage biopharmaceutical company headquartered at 280 East Grand Avenue, South San Francisco, California, developing oral therapies for immune-mediated diseases. Incorporated in 2021 as Esker Therapeutics and renamed Alumis in January 2022, its pipeline is led by envudeucitinib, an oral allosteric TYK2 inhibitor in Phase 3 for moderate-to-severe plaque psoriasis and systemic lupus erythematosus; A-005, a CNS-penetrant TYK2 inhibitor for neuroinflammatory and neurodegenerative disease; and lonigutamab, a subcutaneously delivered anti-IGF-1R antibody for thyroid eye disease. Alumis describes a proprietary precision data-analytics platform that integrates genetic, genomic, proteomic, biological and clinical insight, but it is an internal therapeutic-development capability and is not exposed publicly. The company publishes no developer portal, API documentation, SDKs or machine-readable specifications.

Alumis is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Healthcare.

🌐 Visit website 📡 Source on GitHub

7.9/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyPharmaceuticalsLife SciencesHealthcareImmunologyDrug DevelopmentClinical Trials

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 7.9/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Commercial Clarity 1.8 / 17

Operational Transparency 0.0 / 11

Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 1.9 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/alumis: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 6

The organization behind the API

Website

Website

About

About

Careers

Careers

LinkedIn

Twitter

Twitter

InvestorRelations

InvestorRelations

Other 1

Properties that don't map to a standard resource type

SecondaryMarket

SecondaryMarket

Source (apis.yml)

aid: alumis
name: Alumis
description: 'Alumis Inc. (NASDAQ: ALMS) is a clinical-stage biopharmaceutical company headquartered at 280 East Grand Avenue,
  South San Francisco, California, developing oral therapies for immune-mediated diseases. Incorporated in 2021 as Esker Therapeutics
  and renamed Alumis in January 2022, its pipeline is led by envudeucitinib, an oral allosteric TYK2 inhibitor in Phase 3
  for moderate-to-severe plaque psoriasis and systemic lupus erythematosus; A-005, a CNS-penetrant TYK2 inhibitor for neuroinflammatory
  and neurodegenerative disease; and lonigutamab, a subcutaneously delivered anti-IGF-1R antibody for thyroid eye disease.
  Alumis describes a proprietary precision data-analytics platform that integrates genetic, genomic, proteomic, biological
  and clinical insight, but it is an internal therapeutic-development capability and is not exposed publicly. The company
  publishes no developer portal, API documentation, SDKs or machine-readable specifications.'
image: https://www.alumis.com/themes/default/images/logo.svg
url: https://raw.githubusercontent.com/api-evangelist/alumis/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Healthcare
- Immunology
- Drug Development
- Clinical Trials
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/alumis-domain-security.yml
- type: Website
  url: https://www.alumis.com/
- type: About
  url: https://www.alumis.com/about/
- type: Careers
  url: https://www.alumis.com/careers/
- type: PrivacyPolicy
  url: https://www.alumis.com/privacy-policy/
- type: LinkedIn
  url: https://www.linkedin.com/company/alumis-co/
- type: Twitter
  url: https://twitter.com/_Alumis
- type: InvestorRelations
  url: https://investors.alumis.com/
- type: SecondaryMarket
  url: https://forgeglobal.com/alumis_stock/
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 1
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Alumis is a clinical-stage biopharmaceutical company whose product is oral TYK2/IGF-1R drug candidates, not software;
    its site has only about/science/pipeline/patients/careers sections and every developer-shaped path (/developers, /api,
    /docs, /openapi.json, /graphql, /llms.txt, /.well-known/*) returns a hard 404, and the only "alumis" GitHub org is an
    unrelated Scandinavian TypeScript/C# shop.
  evidence:
  - url: https://www.alumis.com/developers
    status: 404
  - url: https://www.alumis.com/openapi.json
    status: 404
  - url: https://www.alumis.com/.well-known/agent-card.json
    status: 404
  - url: https://www.alumis.com/llms.txt
    status: 404
  - url: https://www.alumis.com/
    status: 200
  checked: '2026-08-06'